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Objectives. We sought to evaluate the efficacy of alpha-
adrenergic blocking agents in counteracting left ventricular (LV)
dysfunction occurring after transient ischemia in humans.
Background. The mechanisms underlying postischemic LV
dysfunction are largely unknown.
Methods. Percutaneous transluminal coronary angioplasty
(PTCA) provides a clinical model of ischemia and reperfusion. In
50 patients undergoing coronary stenting for 77 6 5% stenosis, LV
function was monitored by transesophageal echocardiography
during and 30-min after PTCA. Fifteen minutes after stenting, 15
patients received 12 mg/kg body weight of the alpha-blocker
phentolamine intracoronarily, 15 patients received 600 mg/kg of
the alpha1-blocker urapidil intravenously, 10 patients received the
combination of phentolamine and 1.2 mg of propranolol intra-
coronarily, and 10 patients received saline.
Results. Fifteen minutes after successful coronary dilation,
significant contractile dysfunction occurred in previously isch-
emic and nonischemic myocardium. LV dysfunction was accom-
panied by an increase in coronary resistance and diffuse vasocon-
striction. Alpha-blockers counteracted LV dysfunction and
coronary resistance and the increase in vasoconstriction. Phen-
tolamine and urapidil increased global LV shortening from 34 6
9% to 45 6 8% and to 49 6 8%, respectively (p < 0.05). After the
administration of propranolol combined with phentolamine, LV
dysfunction remained unchanged (34 6 6%), as in control sub-
jects.
Conclusions. LV dysfunction occurs after PTCA, as described in
animal models after ischemia. Alpha-blockers abolished LV,
macrocirculatory and microcirculatory dysfunction, whereas the
alpha-blocker effect was prevented by combining alpha- and
beta-blockers. The evidence of diffuse rather than regional dys-
function, together with the opposite effects of alpha- and beta-
blockade, supports the hypothesis of neural mechanisms eliciting
postischemic LV dysfunction.
(J Am Coll Cardiol 1998;31:992–1001)
©1998 by the American College of Cardiology
In 1935 brief periods of myocardial ischemia in open chest
dogs (1) were reported to impair systolic shortening. In 1975
Heyndrickx et al. (2) described, in conscious dogs, that brief
periods of myocardial ischemia, too brief to cause necrosis,
were followed by a long-lasting impairment of contractile
function and of regional blood flow (3), a phenomenon that
was later called myocardial “stunning” (4). In humans percu-
taneous transluminal coronary angioplasty (PTCA), clinically
used as a means to correct coronary artery stenoses, entails the
induction of periods of transient ischemia. However, it is
controversial whether or not transient ischemia, as produced
by PTCA in humans, leads to left ventricular (LV) dysfunction
(5–7). It has been shown that coronary artery constriction
occurs soon after dilation (8) and persists for a rather long time
(9). In addition, coronary vascular resistance has been reported
to increase (10) and coronary flow reserve to be impaired
(11–13). In a previous study (10) we have shown that PTCA in
patients produces a delayed coronary artery constriction that is
mediated by activation of alpha-adrenergic mechanisms, likely
to be reflexly induced by stretching of the dilated coronary
artery and stimulation of coronary mechanoreceptors (14–16).
This coronary artery constriction was diffuse and not limited to
the dilated artery, and furthermore was simultaneously accom-
panied by an increase of coronary artery resistance (10). The
intracoronary injection of drugs interfering with sympathetic
nervous system activity was able to counteract the reduction in
coronary diameter and the increase in coronary artery resis-
tance.
The goal of the present investigation was to test the
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hypothesis that, in humans, transient myocardial ischemia, as
induced by PTCA, is followed by LV dysfunction. As an
additional goal we assessed whether counteracting post-PTCA
reflex coronary artery constriction and the simultaneous in-
crease in coronary vascular resistance by means of alpha-
blockers (10), thus allowing for a fuller restoration of flow,
might prove beneficial to LV performance (2,3).
Methods
Patients. We studied 50 patients (9 women and 41 men,
mean age 61 6 11 years) undergoing coronary dilation fol-
lowed by coronary stenting for 77 6 5% (mean 6 SD)
epicardial vessel stenosis. Vessel diameters were measured by
quantitative coronary angiography (Artrek) (17). Three diam-
eters were prospectively chosen on the basal angiogram along
the PTCA vessel (stenosis, normal reference and distal level)
and one at the distal level of the control vessel (Table 1),
following the schema previously reported by us as well as by
other investigators (8–10). The same diameters were subse-
quently measured in the following conditions. Thirty patients
had left anterior descending coronary artery (LAD) stenosis,
and 12 had right coronary artery (RCA) and 8 had left
circumflex lesions. All patients were admitted to the Clinique
Pasteur for recurrent or unstable angina. All gave written,
informed consent to the study, which had been approved by the
Clinique Pasteur Ethical Committee.
Medical treatment. All patients were pretreated with con-
ventional antianginal drugs such as nitrates, calcium antago-
Abbreviations and Acronyms
CBF(V) 5 coronary blood flow (velocity)
CSA 5 cross-sectional area (cm2)
CVRi 5 coronary vascular resistance index
FAC 5 percent fractional area change
LAD 5 left anterior descending coronary artery
LV 5 left ventricular
PTCA 5 percutaneous transluminal coronary angioplasty
RCA 5 right coronary artery
TEE 5 transesophageal echocardiography
WTH 5 percent systolic wall thickening
Table 1. Effects of Procedure and Drugs on Coronary Diameters
Drug Group
No. of
Pts
Pre-PTCA
Diameter
(mm)
Percent
Stenosis
Diameter
Soon After
Stenting
(mm)
Diameter
15 min After
Stenting
(mm)
Percent
Change
Drug
Effect
(mm)
Percent
Change
Phentolamine, 12 mg/kg ic
PTCA vessel, normal reference 15 3.19 6 0.6 3.23 6 0.5 2.73 6 0.4* 213 6 9* 3.56 6 0.6* 12 6 7*
PTCA vessel, stenosis level 15 0.65 6 0.2 80 6 4% 3.27 6 0.5* 3.14 6 0.6* — 3.36 6 0.5* —
PTCA vessel, distal level 15 1.80 6 0.5 — 1.88 6 0.4 1.45 6 0.4* 219 6 6* 2.17 6 0.3* 21 6 8*
Control vessel, distal level 12 1.92 6 0.4 — 1.94 6 0.4 1.52 6 0.3* 221 6 6* 2.20 6 0.3* 15 6 6*
Propranolol, 1.2 mg ic, plus phentolamine,
12 mg/kg ic
PTCA vessel, normal reference 10 3.36 6 0.9 3.31 6 0.9 2.80 6 0.7* 217 6 4* 2.92 6 0.5* 211 6 11*
PTCA vessel, stenosis level 10 0.73 6 0.2 78 6 6% 3.22 6 0.9* 3.18 6 0.8* — 3.18 6 0.8* —
PTCA vessel, distal level 10 2.34 6 0.8 — 2.21 6 0.7 1.94 6 0.6* 212 6 4* 1.84 6 0.6* 221 6 9*
Control vessel, distal level 9 2.18 6 0.7 — 1.96 6 0.5 1.74 6 0.6* 220 6 6* 1.69 6 0.6* 223 6 10*
Urapidil, 600 mg/kg iv
PTCA vessel, normal reference 15 2.99 6 0.5 2.94 6 0.4 2.54 6 0.5* 215 6 9* 3.34 6 0.4* 12 6 10*
PTCA vessel, stenosis level 15 0.74 6 0.5 75 6 4% 2.89 6 0.4* 2.90 6 0.4* — 2.95 6 0.4* —
PTCA vessel, distal level 15 1.95 6 0.4 — 1.89 6 0.5 1.52 6 0.4* 223 6 9* 2.34 6 0.6* 20 6 12*
Control vessel, distal level 8 1.67 6 0.2 — 1.67 6 0.2 1.42 6 0.2* 215 6 7* 1.94 6 0.2* 17 6 9*
Saline, 5 ml ic
PTCA vessel, normal reference 10 3.02 6 0.4 2.99 6 0.4 2.59 6 0.4* 214 6 6* 2.47 6 0.4* 218 6 8*
PTCA vessel, stenosis level 10 0.78 6 0.2 74 6 6% 2.93 6 0.4* 2.95 6 0.4* — 2.95 6 0.4* —
PTCA vessel, distal level 10 2.02 6 0.3 — 1.95 6 0.3 1.67 6 0.2* 215 6 4* 1.64 6 0.3* 219 6 6*
Control vessel, distal level 9 1.97 6 0.6 — 1.94 6 06 1.64 6 0.5* 217 6 6* 1.64 6 0.5* 217 6 6*
Mean values
PTCA vessel normal reference 50 3.13 6 0.6 3.10 6 0.6 2.65 6 0.5* 214.6 6 8*
PTCA vessel stenosis level 50 0.72 6 0.2 77 6 5% 3.05 6 0.6* 3.02 6 0.6* — — —
PTCA vessel, distal level 50 2.03 6 0.6 — 1.98 6 0.5 1.63 6 0.5* 220 6 7* — —
Control vessel, distal level 38 1.90 6 0.5 — 1.85 6 0.5 1.55 6 0.4* 218 6 7* — —
*p , 0.05 as compared with diameter before PTCA. Data presented are mean value 6 SD or number of patients (Pts). Coronary diameter measurements were
obtained by means of quantitative coronary angiography (Artrek) in the basal condition (before PTCA), soon after stenting, 15 min after stenting and at the time of
the maximal effect of the drugs (10 min after urapidil and phentolamine, 15 min after the combination of phentolamine and propranolol or saline). A significant
reduction in vessel diameter occurred 15 min after stenting, except inside the stent. The intrastent diameter increased somewhat with the Wallstent implantation.
Phentolamine and urapidil induced a significant vasodilation, whereas the combined injection of propranolol and phentolamine or saline did not. ic 5 intracoronary;
iv 5 intravenous; PTCA 5 percutaneous transluminal coronary angioplasty.
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nists (diltiazem, 180 to 360 mg/day) and antiplatelet drugs
(aspirin, 250 mg/day for at least 7 days, and ticlopidine, 250 mg
twice daily for the preceding 72 h). If it was part of the ongoing
therapy, beta-blockers were withdrawn 72 h before the study.
At the beginning of the dilation procedure patients received
neuroleptic analgesia with droperidol (2 to 10 mg intrave-
nously) and phenoperidine (0.6 to 1 mg intravenously) (10).
The doses were adjusted during the study to keep the patient
sedated. Heparin, 150 U/kg, was used for anticoagulation.
Nitric oxide donors, linsidomine (1 mg) and isosorbide dini-
trate (1.5 mg) were injected before balloon inflation to make
the final stent expansion match, in diameter, with the vessel in
a state of dilation. Nitric oxide donors were always adminis-
tered after obtaining baseline coronary diameters and pre-
PTCA LV function.
Measurements of LV function. Beginning 10 min before
the dilation procedure and continuously throughout the study,
up to 30 min after stent deployment, LV function was contin-
uously monitored by means of transesophageal echocardiogra-
phy (TEE) (18) using a 5.0-MHz multiplane probe (SONOS
2500, Hewlett Packard Co.). Before positioning the guiding
catheter, with the patient already sedated, the TEE probe was
introduced and a transgastric view of the left ventricle at the
level of papillary muscles was obtained (short-axis view). The
images were acquired on a SVHS Panasonic videotape re-
corder and subsequently analyzed by means of a Freeland-
TomTec Imaging System with Integrated Cardiac Analysis
Software, Version 5, to obtain quantitative analysis. Starting
40 ms after the electrocardiographic (ECG) R wave, eight
frames through a single cardiac cycle were automatically
selected and digitized. Afterward the frames with maximal and
minimal LV area were selected and end-diastolic and end-
systolic endocardial borders were manually traced. Global and
regional LV function were automatically calculated as percent
fractional area change (FAC) and percent systolic wall thick-
ening (WTH), respectively, according to the following formu-
las:
FAC ~%! 5
~LV end-diastolic area 2 LV end-systolic area!
LV end-diastolic area
3 100;
WTH ~%! 5
Systolic 2 Diastolic wall thickness
Diastolic wall thickness
3 100.
LV diastolic area was also used as an indirect index of
preload (19).
For regional LV analysis, diastolic and systolic wall thick-
nesses and WTH were assessed from the short-axis view at 0,
3, 6 and 9 o’clock, with zero representing the posterior wall
(RCA-supplied region), 3 the lateral wall (region supplied by
left circumflex coronary artery), 6 the anterior wall (LAD-
supplied region) and 9 the mid-septum (LAD-supplied region
or RCA-supplied region in case of a dominant RCA). In the
final evaluation, regions were also defined as PTCA and
non-PTCA, depending on the vessel that underwent dilation.
FAC and WTH were calculated in 1) the basal condition
(before PTCA); 2) soon after coronary stenting; 3) 15 min after
coronary stenting (i.e., when coronary artery constriction has
been described [8–10]); and 4) 5 to 15 min after pharmacologic
intervention.
Intraobserver variability was assessed by having one ob-
server (G.B.A.) remeasure FAC and WTH twice in 10 subjects
at all phases of the study. To assess interobserver variability in
15 subjects, the same indexes were measured also by a second
observer (M.K.) at all phases of the study.
Coronary blood flow velocity. Phasic and mean coronary
blood flow velocity (CBFV, cm/s) were obtained with a pulsed
Doppler flow meter (Triton Technology, model 100-1000-20C)
and 3F Doppler catheters (Nyros-Sorin) that were positioned
;10 mm above the stenosis, as previously described (10). The
technique has been fully validated (20). The Doppler catheter
was withdrawn during coronary dilation and reinserted over
the wire in the same position after coronary stenting. Two
ECG leads were continuously recorded. Arterial blood pres-
sure was measured through the guiding catheter at the coro-
nary ostium. Cross-sectional area (CSA) was obtained with the
aid of quantitative coronary angiography (Artrek) (17). Coro-
nary blood flow (CBF) (ml/min) and a calculated index of
coronary vascular resistance (CVRi) were obtained as previ-
ously described (21). In view of the approximations inherent in
this procedure, we report only directional and relative varia-
tions as percent changes (mean 6 SD) from pre-PTCA values.
Coronary stenting. Two or three balloon inflations of
3 min, each followed by 2 min of reperfusion, were performed
to predilate the artery before inserting the stents. A single stent
or multiple stents (Palmaz-Schatz, GT-Roubin II or Wall-
Stent) were implanted in the lesion to properly reconstruct the
anatomy of the vessel. Stents were deployed with a 20/30-s
balloon inflation followed by other high pressure inflations (3
to 5 inflations at 18 to 22 atm for 30/60 s) to expand the struts
up to the nominal normal reference vessel diameter (Table 1).
The smallest guiding catheter size compatible with the type of
stent was chosen, and the tip of the guiding catheter was
slightly withdrawn from the coronary ostium, when not re-
quired by the procedure, to avoid flow reductions.
Pharmacologic interventions. Fifteen minutes after coro-
nary stenting and after documenting LV function, 15 patients
received 12 mg/kg of phentolamine intracoronarily (nonselec-
tive alpha-blocker: Regitin, 10-mg vials, Novartis, Switzer-
land), 15 patients received 600 mg/kg of urapidil (24,25)
intravenously (from 35 to 48 mg intravenously) (alpha1-
selective blocker: Ebrantil, 50-mg vials, Byk Gulden, Germany)
and 10 patients received the combination of 12 mg/kg of
phentolamine and 1.2 mg of propranolol (nonselective beta-
sympathetic blocker: Inderal, 5-mg vials, Zeneca) intracoro-
narily. As the alpha1-blocker we chose urapidil because this
drug induces a central serotoninergic activation of brain
5HT1A receptors, which may be responsible for the smallness
of reflex tachycardia, despite the pronounced vasodilation
(22,23). The doses of alpha- and beta-blockers were lower than
those used in other studies (24) and were titrated to obtain an
alpha- or beta-blocking effect without decreasing blood pres-
sure (10). In 10 control subjects, 5 ml of warm saline was
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injected intracoronarily. The short-axis view was monitored by
TEE for an additional 15 min to assess the effects of different
pharmacologic interventions. All study investigators, except
the one responsible for drug dilution, were unaware of the
administered agent. All off-line measurements were performed
in a blinded manner.
Statistical analysis. The results are expressed as the mean
value 6 SD. One- or two-way analysis of variance for repeated
measures was performed with a commercial package, as ap-
propriate. To assess statistical significance between the groups,
the Scheffe´ F test was applied, with a value of p , 0.05 as
significant. In view of the large interindividual variability of the
absolute values, multiple comparisons between the groups
were performed with normalized data (%). Regression analysis
was performed by the least squares technique. Agreement
between the readings performed by two observers was evalu-
ated by estimating the consistent bias between readings, as
recommended by Bland and Altman (25) for the comparison
of two methods of clinical measurements.
Results
Effect of coronary stenting on LV function and on coronary
diameters. Fractional area change and end-diastolic area
measured at various conditions are shown in Figure 1. Coro-
nary stenting slightly increased FAC from 41 6 9% to 43 6 7%
(mean of all patients). After stenting, myocardial function
progressively worsened in all myocardial regions, reaching its
lowest level 15 min later, as indicated by a decrease in FAC
from 43 6 7% soon after stenting to 34 6 9% 15 min after
coronary stenting (p , 0.05 vs. before PTCA) (Fig. 1). Also,
LV diastolic area significantly increased 15 min after coronary
stenting. The changes in regional function are more clearly
shown in Figure 2 and Table 2. Soon after coronary stenting,
systolic thickening significantly increased in the myocardium
supplied by the dilated vessel, whereas no changes were
observed in normally perfused regions. Surprisingly, 15 min
later, the reduction in thicknesses and in systolic thickening
occurred not only in PTCA regions but also in surrounding
territories that did not undergo transient ischemia (non-PTCA
regions). Figure 3 represents the computer printouts of systolic
and diastolic LV endocardial contour of two different pa-
tients—one receiving urapidil and the other a combination of
phentolamine and propranolol 15 min after coronary stenting.
Both patients showed a clear increase in percent systolic
thickening soon after stenting and severe worsening 15 min
Figure 1. Left ventricular FAC (top) (%, mean 6 SD) and diastolic
area (cm2) (bottom) obtained from the endocardial diastolic and
systolic contours (TomTec) before PTCA (Pre-PTCA), soon after
coronary stenting (Post-Stent), 15 min after stenting (15 min Post-S)
and after pharmacologic interventions. Phentolamine and urapidil
significantly increased FAC and decreased diastolic area. When alpha-
and beta-blockers combined or saline was injected, no effects on FAC
or diastolic area were observed. No changes in diastolic area were
observed after drug administration versus pre-PTCA condition. 5 min
Phe 5 5 min after intracoronary (ic) phentolamine injection; Phe 5
phentolamine; Pro 5 propranolol; 5 min Ura 5 5 min after urapidil
intravenous injection; 15 min Saline 5 15 min after saline.
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later. The occurrence of LV global dysfunction corresponded
to diffuse coronary artery constriction (Table 1). In fact, 15 min
after stenting, a 220 6 7% and 218 6 7% reduction in
coronary diameter, as compared with the diameter before
PTCA (p , 0.05), was measured at the distal level of the
dilated and control vessel, respectively.
Intraobserver variabilities for FAC and WTH were 4.2 6
2.1% and 4.4 6 3.0%, respectively. Interobserver variabilities
for the same indexes were 5.7 6 3.0% and 5.3 6 3.2%,
respectively. A plot of the difference between the two observ-
ers for each measurement versus the mean of the two mea-
surements showed a mean difference of 0.14 6 2.63% and
20.25 6 2.55%, respectively, with good agreement because all
points but two were within 62 SD (Fig. 4).
Figure 2. Systolic wall thickening (mean 6 SD) measured in myocar-
dial regions undergoing coronary dilation (top) and in regions not
subtended by the dilated vessel (bottom). Systolic wall thickening
significantly increased soon after coronary stenting only in PTCA
regions, whereas 15 min after dilation a significant reduction occurred
in myocardium both subtended and not subtended by the dilated
vessel. Five minutes after the injection, phentolamine and urapidil
significantly increased systolic thickening. When the combination of
propranolol and phentolamine was simultaneously injected or saline
was administered to control subjects, the impairment in systolic
thickening was still present. Pro 1 Phe 5 propranolol combined with
phentolamine.
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Effect of stenting on CBF and CVRi. The effects of coro-
nary stenting on blood flow measurements obtained in the
proximal dilated coronary vessel are reported as normalized
mean (6SD) values in Figure 5. Average basal CBFV was
9.2 6 2 cm/s; CSA was 11.3 6 4 mm2; CBF was 61.7 6
23 ml/min; and CVRi was 1.69 6 0.5 U. With the condition
before drug injections (before PTCA, soon after and 15 min
after stenting) similar in all groups, the data were grouped
together. Soon after stent implantation no changes were
observed in CBFV, CSA, CBF and CVRi. In fact, CBFV
increased by 15.3 6 12% (p 5 NS), CSA by 2.5 6 6% (p 5 NS)
and CBF by 18.3 6 16% (p 5 NS), whereas CVRi decreased
by 215.4 6 11% (p 5 NS). Fifteen minutes after coronary
stenting, CBFV decreased by 223.6 6 16%, CSA by 218.5 6
12% and CBF by 238.4 6 15% (p , 0.05), whereas CVRi
increased by 66.2 6 13% (p , 0.05) (Fig. 5).
Hemodynamic effects of drugs. The intravenous injection
of urapidil transiently (1 to 2 min) decreased mean (6SD)
arterial pressure (from 87 6 8 to 73 6 9 mm Hg, p , 0.05) and
did not change heart rate. The intracoronary injection of
12 mg/kg of phentolamine did not significantly change the
hemodynamic variables, whereas 1.2 mg of propranolol com-
bined with 12 mg/kg of phentolamine significantly affected
blood pressure and heart rate.
Effects of drugs on LV dysfunction. Thirty minutes after
PTCA a diffuse reduction in fractional systolic shortening and
thickening and significant coronary artery constriction were
persisting in patients who received intracoronary saline (Fig. 1
and 2, Tables 1 and 2). Both the alpha1-adrenergic blocker
urapidil and the nonselective alpha-blocker phentolamine sig-
nificantly improved SWT and counteracted coronary artery
constriction (Tables 1 and 2, Fig. 2). When the beta-
sympathetic blocker propranolol was combined with phentol-
amine, no significant changes in SWT or in coronary diame-
ters, as compared with 15 min after stenting, were observed. In
fact, LV dysfunction and vasoconstriction were persisting, as in
patients receiving saline. As shown in Figure 3, LV dysfunction
was abolished by the intravenous injection of urapidil (top
right panel), whereas it persisted after the administration of
propranolol and phentolamine (bottom right panel).
Effect of drugs on CBF and coronary vascular resistance.
The intracoronary administration of phentolamine or urapidil
significantly increased CBF by 74.8 6 21% and 51.9 6 19%,
respectively, and decreased CVRi by 246 6 11% and 235 6
9%, respectively (p , 0.05) (Fig. 5). The combined adminis-
tration of propranolol and phentolamine, as well as saline, did
not change CBF or CVRi, as compared with 15 min after
coronary stenting, when a condition of global LV dysfunction
was present.
Discussion
Our study provides clear evidence that coronary stenting,
despite the removal of a flow-limiting stenosis, is followed by a
significant impairment of LV myocardial function (2–4), which
is associated with a significant reduction in flow. The beneficial
Figure 4. A plot of the differences in measured values between two
observers, both for FAC and systolic thickening (THK), versus the
mean of measured values.
Figure 3. Digitized printouts from the short-axis
(SAX) left ventricular images by TEE (TomTec
Imaging System) obtained from drawing the sys-
tolic and diastolic endocardial contour of two
patients undergoing beta1-blockade and alpha-
and beta-blockade 15 min after stenting. The
upper sequence shows images of Patient 41 (33-
year old man) who had a 95% mid-LAD stenosis.
Before PTCA, hypokinesia of the mid and poste-
rior septum was present. Soon after stent implan-
tation, the hypokinesia disappeared. Fifteen min-
utes after stenting, a significant global reduction
of LV FAC occurred. The intravenous injection
of 34 mg of urapidil abolished LV dysfunction.
The lower sequence shows printouts of Patient 50
(53-year old man) who had a 82% mid-RCA
stenosis. After stenting, FAC increased to 43%.
Fifteen minutes after dilation, a significant global
LV dysfunction (30% FAC) occurred. The intra-
coronary injection of propranolol and phentol-
amine did not modify FAC.
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effect of intracoronary alpha-blockers suggests a causative role
of reflex sympathetic interaction.
Effect of coronary stenting on LV function. The observa-
tion that coronary stenting is followed by LV dysfunction is in
agreement with a previous report by Sheiban et al. (7), who
described the occurrence of myocardial stunning in patients
undergoing 5-min balloon inflations. In our study, two infla-
tions of 3 min were performed to predilate the coronary artery,
but additional inflations followed by very short reperfusions
were carried out to deploy the stent. These additional high
pressure inflations may have further increased the artery
stretching, which has been demonstrated, in animal studies, to
activate cardiac sympathetic afferent fibers (14–16,26,27) and
may have exerted a cumulative ischemic effect. Our observa-
tion is at variance with the results of other studies (5,6) that
assessed ventricular function during a shorter interval from the
end of the last inflation (5) or after a single 1-min inflation (6).
In contrast to previous reports, in our study LV function was
assessed with the aid of continuous TEE, which has been
shown to allow reliable quantitative measurement of LV global
and regional function (18,19). In fact, the TEE short-axis view
displays in sequence systolic and diastolic excursions and
simultaneously allows measurement of systolic and diastolic
thickness, as well as thickening in myocardial wall sectors
supplied by different coronary rami.
Effect of coronary stenting on flow and resistance. The
occurrence of global LV dysfunction corresponded in timing
and time course to the angiographic phenomenon of coronary
artery constriction, which is also a diffuse phenomenon involv-
ing both dilated and nonmanipulated control vessels, as previ-
ously observed by us (10) and other investigators (28). More-
over, vasoconstriction was also demonstrated to occur after
PTCA along renal (27) and limb (29) vessels. The reduction in
epicardial coronary artery diameter was followed by a simul-
taneous microvascular constriction. Both these phenomena are
abolished by alpha-adrenergic blockade (10). For this study, we
selected a cohort of patients who, because of the irregular
anatomy of their plaques, would be better treated by coronary
stenting, which allows for complete dilation of the lesion and
removes the mechanical obstruction to flow. This is, to our
knowledge, the first demonstration, in humans, that flow
reductions occur simultaneously with LV dysfunction, al-
though the relation between the reduction in regional coronary
perfusion and cardiac function has been demonstrated for a
long time in animal studies (3,30). Indeed, in our patients, the
reduction in systolic shortening and the evidence of macrovas-
cular and microvascular perfusion abnormalities were more
sensible indexes of postischemic LV dysfunction (31), as
compared with ECG changes, which were negligible 15 min
after stenting.
LV dysfunction. Regional rather than global contractile
LV dysfunction is commonly believed to occur as a conse-
quence of regional ischemia, with sparing of areas not involved
in the ischemic process (2–4,7,31). This observation comes
from animal studies, in particular from conscious dog models
in which a close correlation between regional blood flow and
regional contractile function was found after transient myocar-
dial ischemia (2–4,31–33). In particular, in animal models, an
increase in regional vascular resistance and a reduction of
vasodilator responsiveness to intravenous adenosine and pa-
paverine were observed to occur simultaneously with the
presence of LV dysfunction (32,33). In contrast, we have
Figure 5. CBFV, CSA, CBF and CVRi calculated
as percent changes from basal values (average
[6SD] basal values 9.2 6 0.7 cm/s, 11.3 6 4.2 mm2,
61.7 6 23 ml/min and 1.69 6 0.5 U, respectively).
Because the conditions before drug injections
(Soon After Stent and 15 min After Stent) were
similar in all groups, these data were grouped
together. Coronary stenting did not affect CBFV,
CSA or CBF. Fifteen minutes after the end of the
dilation procedure, a significant increase in CVRi
was observed. Phentolamine and urapidil reduced
CVRi, whereas no effects were observed after the
combination of propranolol and phentolamine.
*p , 0.05 versus pre-PTCA values.
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observed that in humans, brief coronary balloon occlusions
induce LV dysfunction, which also occurs in regions not
undergoing transient ischemia. In contrast to previous reports
(5–7) that did not observe global LV dysfunction, our obser-
vation may have been favored by acquiring images by means of
TEE. Our observation is in agreement with the recent finding
that remote regional dysfunction is present in patients with
myocardial infarction and single-vessel disease (34). Our find-
ings are also consistent with evidence of an altered vasodilator
reserve and metabolism in the myocardium supplied by appar-
ently normal coronary arteries (35,36) in patients with single-
vessel disease or in patients with coronary spastic angina (37).
In fact, our data suggest that coronary artery constriction, a
reduction in CBF and an increase in coronary vascular resis-
tance are different facets simultaneously accompanying LV
dysfunction. The apparently smooth aspect of the coronary
tree on the angiogram does not exclude the presence of a
diffusely altered endothelium (21,38) or of subendothelial
plaques (39), which cause the artery to react paradoxically to
physiologic vasodilator stimuli such as acetylcholine (40,41),
serotonin (40,42–44), adenosine (13,45) and others (40). The
discrepancies observed in our study as compared with
previous reports may also be ascribed to a diffusely altered
endothelium.
Myocardial dysfunction is usually thought to reflect an
adjustment of coronary flow to preserve the perfusion contrac-
tion matching in several acute and chronic ischemic states (4),
including coronary vasospasm (46) occurring in the absence of
a flow-limiting stenosis, and is often considered a protection
mechanism (47) by which the ischemic myocardium slows the
rate of adenosine triphosphate utilization (48) and preserves
its cells from an energy supply reduction by a decrease of
energy demand (2–4). Adrenergic vasoconstriction might be
beneficial in the presence of ischemia by lessening transmural
steal during myocardial hypoperfusion (47). Obviously, this
interpretation must be at least partly revised as a consequence
of the observation that LV dysfunction also occurs in parts of
the myocardium that are not ischemic and have not undergone
a transient restriction of blood flow during the PTCA procedure.
Role of alpha-adrenoreceptors in LV dysfunction. The
observation that the myocardium not exposed to transient flow
standstill undergoes mechanical dysfunction suggests that neu-
ral mechanisms may play a major role in this phenomenon.
Cardio-cardiac sympathetic reflexes, which have been de-
scribed in animals (14–16,28,47,48) and hypothesized in hu-
mans (10,29,30), may represent the link between the area
subjected to transient ischemia and other LV regions and
exaggerate the effects of mechanisms such as “oxyradical”
production (32,33,49), calcium overload (32,50,51) or release
of endothelial factors (52). In fact, experimental studies sug-
gest that impaired calcium homeostasis, resulting in a transient
calcium overload, might be involved in myocardial stunning
(7,50,51). All of our patients were pretreated with full doses of
calcium antagonists, which attenuate myocardial stunning in
case of pretreatment (51). This treatment might have reduced
the occurrence of LV dysfunction. Although coronary stenting
is likely to extensively damage the endothelium of the dilated
vessel, endothelial factors might have contributed to the
delayed occurrence of vasoconstriction. Local nitric oxide
release, likely following wall shear stress changes induced by
stenosis removal, may be responsible for the significant in-
crease in systolic thickening, which soon after dilation was
observed only in regions supplied by the dilated vessel. In
addition, endothelin release might have influenced the changes
in vessel diameter (52). Indeed, in vivo shear stress–dependent
tone or nitric oxide–induced vasodilation is modulated by
inhibition of the adrenergic vasoconstriction (53,54). Although
we did not measure total peripheral resistance, the hypothesis
that the effect of alpha-blockers might in part be ascribed to an
unloading of the LV is made unlikely by the observation that
significant changes in blood pressure or in LV diastolic area
did not occur at the time of post-drug measurements. Indeed,
in our patients, the injection of alpha-blockers increased SWT
and myocardial shortening after infusion (55), counteracting
LV dysfunction and the abnormalities in macrocirculatory and
microcirculatory coronary flow, whereas the simultaneous ad-
ministration of beta- and alpha-blockers blunted the effect of
alpha-blockers alone, unmasking the presence of a beta-
sympathetic inotropic and vasodilator tone (56). After coro-
nary stenting, mechanical, contractile, macrocirculatory and
microcirculatory adjustments take time. This might be due to
the fading effect on cardiac contractility (57) of nitrates
administered intracoronarily to better adjust the final stent size
to a dilated vessel, or it may be due to shear stress mechanisms
occurring soon after coronary dilation (8,57). Indeed, in hu-
mans, at variance with experimental models in which a sympa-
thetic reflex occurs in seconds, the sympathovagal interaction is
reported to be impaired 2 weeks after acute myocardial
infarction (58). The inotropic effect of phentolamine on re-
duced LV performance in acute myocardial infarction was
reported previously by Walinsky et al. (59), who hypothesized
a reflex increase in sympathetic tone 48 h after acute myocar-
dial infarction. In line with this previous study (59), our data
suggest the testable hypothesis that the administration of
alpha-blockers might be beneficial in improving LV dysfunc-
tion after PTCA.
Conclusions. Coronary stenting corrects the mechanical
obstruction to flow but does not induce an immediate recovery
of LV function. Conductance and resistance artery constriction
occurred simultaneously with global LV dysfunction as inter-
related functional and clinical facets of the same phenomenon.
Alpha-sympathetic blockers counteract LV dysfunction, induc-
ing a better perfusion, whereas the combination of alpha- and
beta-blockers has the opposite effect. Neural mechanisms are
most likely regulating these phenomena by cross-talk interac-
tion. These observations may open potential and promising
therapeutic perspectives.
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